Truist initiated coverage of Alnylam (ALNY) with a Buy rating and $385 price target The key near-term value driver for Alnylam is the Amvuttra launch in TTR-CM, which seems to be off to a strong start based on key opinion leader feedback, third party sales data and survey work, the analyst tells investors in a research note. The firm thinks the stock will continue to outperform with strong launch execution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact
- Alnylam Pharmaceuticals Advances Pregnancy Safety Study for Patisiran-LNP
- Alnylam’s ConTTRibute Study: A Closer Look at ATTR Amyloidosis Treatment
- Alnylam’s Promising Huntington’s Disease Study: A Potential Game-Changer
- Alnylam Pharmaceuticals’ Phase 2 Trial: A Potential Breakthrough in Cerebral Amyloid Angiopathy Treatment